PharmaVentures Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA
United Kingdom
Tel: 44-0-1865-784-177
Fax: 44-0-1865-784-178
Website: http://www.pharmaventures.com/
Email: enquiries@pharmaventures.com
10 articles about PharmaVentures Ltd
-
PharmaVentures Ltd Advises The Baylor Scott & White Research Institute On Collaboration With Abzena And Creation Of Denceptor Therapeutics
7/28/2016
-
PharmaVentures Ltd Advises TRANSGENE On The Sale Of Their Biopharmaceutical Manufacturing Plant
2/4/2016
-
PharmaVentures Ltd Completes M&A Deal For Technology In The Stem Cell & Regenerative Medicine Sector
6/30/2015
-
PharmaVentures Ltd Advises MedGenesis Therapeutix In Agreement For Its Potential Therapy For Parkinson's Disease.
9/17/2014
-
PharmaVentures Ltd Appoints Andy Smith as Head of Corporate Finance
10/5/2011
-
PharmaVentures Ltd Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9/9/2011
-
PharmaVentures Ltd Engaged by Avexa Limited to Assist in the Out-licensing of Apricitabine
7/12/2011
-
Merck & Co., Inc. Engages PharmaVentures Ltd to Assist in the Divestment of its Italian Research Centre IRBM
4/24/2009
-
Charles Macfarlane Joins Board Of PharmaVentures Ltd
10/16/2006
-
PharmaVentures Ltd Is Separating Fact From Fiction In The Battle Against Influenza
3/20/2006